A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Mullenders, Jasper ^a   Fabius, Armida W M ^a   Madiredjo, Mandy ^a   Bernards, René ^a   Beijersbergen, Roderick L ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN ARNTL; PROTEIN P53; PROTEIN RBCK1; PROTEIN TNIP1; REGULATOR PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; PROTEIN BMAL1; RBCK1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TNIP1 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LIBRARY; GENE TARGETING; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; NEOPLASM; NUCLEOTIDE SEQUENCE; RELIABILITY; RNA VECTOR; SIGNAL TRANSDUCTION; VALIDATION PROCESS; BIOSYNTHESIS; CELL DIVISION; CELL LINE; GENE VECTOR; GENETICS; INVERTED REPEAT; ISOLATION AND PURIFICATION; OLIGONUCLEOTIDE PROBE; PHYSIOLOGY; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIVISION; CELL LINE; CIRCADIAN RHYTHM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; GENE LIBRARY; GENES, P53; GENETIC VECTORS; HUMANS; INVERTED REPEAT SEQUENCES; OLIGONUCLEOTIDE PROBES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62849106294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004798     Document Type: Article

References (48)

1. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
2. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923.
3. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, et al. (2004) Regulation of p53 activity through lysine methylation. Nature 432: 353-360.
4. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315.
5. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
6. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
8. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
9. http://www-p53.iarc.fr/ IARC p53 Database.
10. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
11. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, et al. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437.
12. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
13. Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, et al. (2006) An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2: 202-206.
14. Bernards R, Brummelkamp TR, Beijersbergen RL (2006) shRNA libraries and their use in cancer genetics. Nat Methods 3: 701-706.
15. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441: 106-110.
16. Silva JM, Marran K, Parker JS, Silva J, Golding M, et al. (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617-620.
17. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, et al. (2008) Cancer proliferation gene discovery through functional genomics. Science 319: 620-624.
18. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, et al. (2006) 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3: 199-204.
19. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, et al. (2006) Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 3: 777-779.
20. Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, et al. (2000) Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103: 1009-1017.
21. Yamanaka K, Ishikawa H, Megumi Y, Tokunaga F, Kanie M, et al. (2003) Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2. Nat Cell Biol 5: 336-340.
22. Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, et al. (1999) The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 145: 1471-1482.
23. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
24. Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41-50.
25. Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3: 350-361.
26. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, et al. (2006) The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22: 375-382.
27. Panda S, Hogenesch JB, Kay SA (2002) Circadian rhythms from flies to human. Nature 417: 329-335.
28. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, et al. (1998) Role of the CLOCK protein in the mammalian circadian mechanism. Science 280: 1564-1569.
29. Lowrey PL, Takahashi JS (2004) Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 5: 407-441.
30. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, et al. (2002) Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109: 307-320.
31. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
32. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
33. Sherr CJ (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673.
34. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
35. Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, et al. (2008) Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122: 1400-1410.
36. Ocker M, Schneider-Stock R (2007) Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374.
37. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, et al. (2003) The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/ WAF1/CIP1 gene. Mol Cell Biol 23: 2669-2679.
38. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, et al. (2001) Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 98: 4510-4515.
39. Heyninck K, Kreike MM, Beyaert R (2003) Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett 536: 135-140.
40. Bayle J, Lopez S, Iwai K, Dubreuil P, De Sepulveda P (2006) The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett 580: 2609-2614.
41. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, et al. (2006) A ubiquitin ligase complex assembles linear polyubiquitin chains. Embo J 25: 4877-4887.
42. Tian Y, Zhang Y, Zhong B, Wang YY, Diao FC, et al. (2007) RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation. J Biol Chem 282: 16776-16782.
43. Tatematsu K, Yoshimoto N, Koyanagi T, Tokunaga C, Tachibana T, et al. (2005) Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins. J Biol Chem 280: 22937-22944.
44. Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP (2006) Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev 20: 1868-1873.
45. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, et al. (2003) Control mechanism of the circadian clock for timing of cell division in vivo. Science 302: 255-259.
46. Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, et al. (2000) Interacting molecular loops in the mammalian circadian clock. Science 288: 1013-1019.
47. Young MW, Kay SA (2001) Time zones: a comparative genetics of circadian clocks. Nat Rev Genet 2: 702-715.
48. Grechez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F (2008) The circadian clock component BMAL1 is a critical regulator of p21WAF1/ CIP1 expression and hepatocyte proliferation. J Biol Chem 283: 4535-4542.